New Vaccines for Autoimmune and Chronic Inflammatory Conditions: Advances, Challenges, and Future Directions

Autoimmune and chronic inflammatory diseases affect nearly 5–10% of the global population and represent a major cause of morbidity, disability, and rising healthcare costs. Traditional therapeutic approaches such as immunosuppressants, biologics, and targeted synthetic agents primarily focus on symptom control or modulation of dysregulated immune pathways. Recently, the concept of therapeutic vaccination has emerged as a transformative strategy designed to induce long-lasting immune tolerance, restore immune homeostasis, and prevent progression of autoimmune pathology. This article reviews recent developments in vaccine platforms aimed at treating autoimmune and chronic inflammatory diseases, focusing on antigen-specific tolerance induction, nanoparticle-based vaccines, peptide immunotherapy, DNA/RNA vaccines, and dendritic-cell–targeted approaches. We also analyze preclinical and clinical findings, discuss safety and ethical considerations, and outline the potential for next-generation personalized tolerogenic vaccines. Finally, key challenges in regulatory oversight, precision target identification, and long-term monitoring are assessed. The review highlights that therapeutic vaccination is becoming one of the most promising frontiers in immunology, with the potential to shift treatment paradigms from generalized immunosuppression to curative, antigen-specific immune reprogramming.